Rituximab as therapy for autoantibody mediated fibromyalgia (RAFT) - proof of concept
Key facts
- Phase
- Phase 3
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorTrial details
- Who runs it
- Region Stockholm – SLSO
- Trial code
- EU 2025-523465-21-00
- Record updated
- 12 February 2026
- Original description
To investigate whether Rx treatment can reduce the average daily pain measured with VAS during week 16 after given treatment with Rx.Read full original descriptionShow less
To investigate whether Rx treatment can reduce the average daily pain measured with VAS during week 16 after given treatment with Rx.
Inclusion: The study participant must have provided written informed consent; The study participants must have been vaccinated with at least three doses of a COVID-19 vaccine or have measurable titers of anti-COVID-19 antibodies; Age 18–65 years; Patients with a diagnosis of fibromyalgia (FM) who meet the diagnostic criteria for FM and have been diagnosed by a treating pain specialist or rheumatologist trained in the use of these criteria (AAPT core diagnostic criteria 1990 and revised criteria from 2016); FM disease duration since diagnosis no more than 2 years, and since symptom onset no more than 5 years; FM disease burden with VAS pain ≥ 50 mm (0-100mm); The patient has tested positive for FM-associated antibodies (Camilla Svensson’s laboratory, Biomedicum, Karolinska Institutet) (2,3), according to current reference intervals; Pain treatment must have been stable without any change in medication or dosage during the 6 weeks prior to screening. For permitted substances, please see section 7.9; Women of childbearing potential must have a negative pregnancy test and use effective contraceptive methods throughout the entire study participation period, from baseline and for one year thereafter; The study participants must be able and willing to comply with all study procedures.
Exclusion: Participation in any other clinical trial of an investigational drug, or exposure to any investigational product or procedure within 6 months prior to screening; Vaccination less than 4 weeks prior to inclusion; Previous use of rituximab for any indication; Any ongoing acute or chronic systemic infection, including HIV, latent tuberculosis, hepatitis B or C, or any other infection considered clinically significant by the study physician and not treated with appropriate antimicrobial therapy; Diagnosis of another autoimmune disease, exclusive stable, substituted hypothyreosis; Severe heart failure (New York Heart Association Class IV) or severe uncontrolled heart disease; Hypersensitivity to the active substance, murine proteins, or any other substance in the investigational medicinal product; Any medical condition that, in the judgment of the study physician, may interfere with the patient’s participation in the study, pose additional risk to the patient, or complicate the assessment of the patient; Any other disease, medical condition, or planned procedure that, in the opinion of the study physician, constitutes a contraindication for participation; Active malignancy within the past 5 years; Severe infection within the past 3 months; BMI > 35; Ongoing or recently discontinued (within the last 6 months) immunosuppressive treatment; Known immunodeficiency; Neuropsychiatric diagnosis; Use of opioids or benzodiazepine; Ongoing or planned pregnancy or breastfeeding.